Company Profile
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: the United States (62.2%), Germany (4.3%), the United Kingdom (3%), Japan (3%), France (2.8%), Canada (2.4%), Spain (2.3%), Italy (2%), Brazil (1.4%), the Netherlands (1.4%) and other (15.2%).
Sales are distributed geographically as follows: the United States (62.2%), Germany (4.3%), the United Kingdom (3%), Japan (3%), France (2.8%), Canada (2.4%), Spain (2.3%), Italy (2%), Brazil (1.4%), the Netherlands (1.4%) and other (15.2%).
Key Executives
Chairman and Chief Executive Officer | |
General Secretary | |
Chief Financial Officer | |
Human Resources Director | |
Director Research & Development |
Key Figures
Millenium | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|
Net sales | 24,334,636 | 21,696,912 | 18,945,290 | 17,834,770 | 17,445,612 |
Cost of sales | 5,536,466 | 4,271,232 | 4,200,994 | 4,348,115 | 4,278,826 |
Payroll | |||||
Operating income | 8,906,944 | 7,153,840 | 3,237,594 | 5,376,058 | 5,521,280 |
Taxes | 1,832,833 | 1,424,693 | 564,751 | 1,142,792 | 427,123 |
Net income | 5,650,366 | 4,882,493 | 1,683,814 | 3,918,144 | 5,006,834 |
Group net income | 5,650,366 | 4,882,493 | 1,683,814 | 3,918,144 | 5,006,834 |
Fiscal year end | 12.16 | 12.15 | 12.14 | 12.13 | 12.12 |
Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
Account Standards |
Shareholder information
BlackRock | |
The Vanguard Group |
Address
AbbVie
1 road North Waukegan
US-IL 60064 North Chicago, Illinois
United States
Phone number: +1 847 932 7900
Fax: +1
http://www.abbvie.com
Please contact MyQuestion.Italy@euronext.com for Company Profile support.